Comparatively, GIPR, which is targeted by dual agonists (e.g., tirzepatide), is expressed in many cancers, while the glucagon receptor (GCGR), which is targeted by triple agonists (e.g., retatrutide), is only detected in a few cancer types (Figure 1). Here, GCGR is linked to cancer.